NCT03583606View on ClinicalTrials.gov

A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z)

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

November 12, 2018

Primary Completion Date

January 14, 2020

Study Completion Date

January 14, 2020

Conditions
Ebola DiseaseImmunisation
Interventions
BIOLOGICAL

ChAd3-EBO-Z

Zaire ebolavirus vaccine administered by an IM injection into the deltoid as a single dose of 2 x 10\^11 virus particles (vp)).

BIOLOGICAL

MVA Multi-Filo Ebola Vaccine

A booster vaccination of replication defective MVA-BN-Filo administered by an IM injection into the deltoid as a single dose of 1 x 10\^8 Infectious Units (IU).

OTHER

Placebo

0.5 mL normal saline administered via IM injection into the deltoid.

Trial Locations (1)

45229-3039

Cincinnati Children's Hospital Medical Center Vaccine Research Center, Cincinnati

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03583606 - A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z) | Biotech Hunter | Biotech Hunter